Billionaire David Abrams’ 10 Stock Picks with Huge Upside Potential

Page 9 of 9

1. Nuvation Bio Inc. (NYSE:NUVB)

Abrams Capital Management’s Stake: $10.14 million

Number of Hedge Fund Holders: 34

Average Upside Potential as of May 8: 194.12%

Nuvation Bio Inc. (NYSE:NUVB) is a clinical-stage biopharmaceutical company that focuses on unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its lead product candidate is taletrectinib, which is a next-generation ROS1 inhibitor for advanced ROS1+ non-small cell lung cancer (NSCLC).

The FDA granted Priority Review to taletrectinib’s NDA with a PDUFA goal date of 23 June 2025, which indicates a potential US launch in mid-2025. Taletrectinib is already approved in China and is being commercialized by Innovent Biologics. A Marketing Authorization Application has been submitted in Japan by Nippon Kayaku as well. Nuvation also launched a US Expanded Access Program in February 2025 for eligible patients.

The upcoming FDA decision on taletrectinib will unlock funding and establish taletrectinib as Nuvation’s first commercial product in the US. On March 12, analyst Soumit Roy of JonesTrading initiated coverage of the stock with a Buy rating and a price target of $10. Roy mentioned that Nuvation Bio Inc. (NYSE:NUVB) is poised to transition to a commercial-stage company by mid-2025. As of December 31, 2024, the company held $502.7 million in cash and marketable securities.

While we acknowledge the growth potential of Nuvation Bio Inc. (NYSE:NUVB), our conviction lies in the belief that AI stocks hold great promise for delivering high returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than NUVB but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 9 of 9